Atossa Therapeutics (Nasdaq: ATOS) has secured a significant patent victory with the issuance of U.S. Patent No. 12,281,056 by the USPTO. The patent includes 58 claims covering (Z)-endoxifen formulations and therapeutic methods for their use.
The new patent specifically protects highly pure and stable enteric oral formulations of (Z)-endoxifen, a potent Selective Estrogen Receptor Modulator (SERM). This development strengthens Atossa's intellectual property portfolio in breast cancer treatment innovation.
Led by CEO Steven Quay, M.D., Ph.D., the company continues to expand its patent estate, which now includes multiple U.S. patents with over 200 patent claims related to (Z)-endoxifen formulations and clinical applications. This strategic protection reinforces Atossa's position in developing targeted therapies for hormone receptor-positive breast cancer.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.